CN111803445B - A kind of preparation method of high stability nanoemulsion and nanoemulsion gel - Google Patents
A kind of preparation method of high stability nanoemulsion and nanoemulsion gel Download PDFInfo
- Publication number
- CN111803445B CN111803445B CN202010660816.2A CN202010660816A CN111803445B CN 111803445 B CN111803445 B CN 111803445B CN 202010660816 A CN202010660816 A CN 202010660816A CN 111803445 B CN111803445 B CN 111803445B
- Authority
- CN
- China
- Prior art keywords
- nanoemulsion
- gel
- nano emulsion
- drug
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/11—Aldehydes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Communicable Diseases (AREA)
- Biophysics (AREA)
- Dispersion Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
技术领域technical field
本发明属于皮肤给药制剂技术领域,具体涉及一种高稳定性纳米乳液及纳米乳凝胶的制备方法。The invention belongs to the technical field of skin drug delivery preparations, and in particular relates to a preparation method of a high-stability nano-emulsion and a nano-emulsion gel.
背景技术Background technique
纳米乳凝胶是指将纳米乳与凝胶基质按照一定比例混合形成的特殊凝胶剂型,该剂型降低纳米乳流动性,提高了纳米乳可应用性。然而现有技术中纳米乳凝胶存在以下技术问题:(1)目前该类剂型制备过程中未考虑pH对纳米乳滴zeta电位影响;(2)现有纳米乳凝胶制备方法存在缺陷,即制备纳米乳、随后将纳米乳与完全交联的等质量凝胶基质混合,无法保证纳米乳滴在纳米乳凝胶中的均匀分布、无法保证该剂型在皮肤中纵向、横向均匀递送药物。Nanoemulsion gel refers to a special gel formulation formed by mixing nanoemulsion and gel matrix in a certain proportion. This formulation reduces the fluidity of nanoemulsion and improves the applicability of nanoemulsion. However, the nanoemulsion gel in the prior art has the following technical problems: (1) the influence of pH on the zeta potential of the nanoemulsion droplets is not considered in the preparation process of this type of dosage form at present; (2) the existing nanoemulsion gel preparation method has defects, namely The preparation of nanoemulsion and subsequent mixing of the nanoemulsion with a fully cross-linked equal-quality gel matrix cannot guarantee the uniform distribution of the nanoemulsion droplets in the nanoemulsion gel and the uniform delivery of the drug longitudinally and transversely in the skin.
目前一现有技术制备了柠檬醛-特比萘芬复方纳米乳凝胶,其通过调节增稠剂含量发现,随增稠剂含量增加(1%,2%和3%),纳米乳凝胶逐渐由透皮给药系统向局部给药系统过渡,24h累积透皮药物量极显著下降(P<0.01),其中柠檬醛由1021μg/cm2降低至353μg/cm2、特比萘芬由213μg/cm2降低至74.3μg/cm2;以BBOT标记纳米乳滴,激光共聚焦显微镜示踪药物分布结果显示,随着增稠剂含量增加,虽然药物倾向沉积于表皮层和真皮浅层,但这种分布并不均匀,即药物递送深浅不一,并且仍有相当量的药物进入真皮层。At present, a prior art has prepared citral-terbinafine compound nanoemulsion gel, which is found by adjusting the content of thickener, with the increase of the content of thickener (1%, 2% and 3%), the nanoemulsion gel The transdermal drug delivery system gradually transitioned from the transdermal drug delivery system to the local drug delivery system, and the cumulative transdermal drug volume decreased significantly (P<0.01) in 24 hours, among which citral decreased from 1021μg/cm 2 to 353μg/cm 2 , terbinafine from 213μg /cm 2 decreased to 74.3μg/cm 2 ; Nanoemulsion was labeled with BBOT, and the results of drug distribution traced by laser confocal microscopy showed that with the increase of thickener content, although the drug tended to be deposited in the epidermis and superficial dermis, This distribution is not uniform, i.e., the drug is delivered in different depths, and a considerable amount of the drug still enters the dermis.
目前另一现有技术以卡波姆940凝胶基质制备了特比萘芬纳米乳凝胶(1%卡波姆940,w/w),透皮试验发现,24h内所制备纳米乳凝胶的透皮速率极显著(P<0.01)高于市售特比萘芬凝胶制剂(兰美抒),体外皮肤白色念珠菌感染治疗试验发现,特比萘芬纳米乳凝胶的真菌清除率显著高于兰美抒组(P<0.01)。At present, another prior art uses carbomer 940 gel matrix to prepare terbinafine nanoemulsion gel (1% carbomer 940, w/w). The transdermal test found that the nanoemulsion gel prepared within 24h The penetration rate of terbinafine was extremely significant (P<0.01) higher than that of the commercially available terbinafine gel preparation (Lamisil). Significantly higher than that in the lamishil group (P<0.01).
然而,现有技术制备得到的纳米乳凝胶一方面动力学稳定性欠佳,另一方面,制备纳米乳凝胶仍采用纳米乳与等质量的、交联完全的凝胶基质充分混合的方法,无法保证纳米乳滴均匀分散于凝胶基质中,造成递送药物在皮肤中纵向、横向分布不均匀的问题。However, on the one hand, the nanoemulsion gel prepared by the prior art has poor kinetic stability; , it is impossible to ensure that the nanoemulsion droplets are evenly dispersed in the gel matrix, resulting in uneven distribution of the delivered drug in the skin longitudinally and laterally.
发明内容SUMMARY OF THE INVENTION
为了解决以上的技术问题,本发明提供一种提高纳米乳凝胶动力学稳定性、提高纳米乳滴分散均匀性的纳米乳凝胶的制备方法。In order to solve the above technical problems, the present invention provides a preparation method of nanoemulsion gel which improves the dynamic stability of nanoemulsion gel and improves the dispersion uniformity of nanoemulsion droplets.
本发明的目的是提供一种高稳定性的纳米乳液的制备方法。The purpose of this invention is to provide a kind of preparation method of high stability nanoemulsion.
本发明的另一目的是利用上述高稳定性纳米乳液制备纳米乳凝胶的方法。Another object of the present invention is to utilize the above-mentioned high stability nanoemulsion to prepare the method of nanoemulsion gel.
根据本发明的具体实施方式的高稳定性纳米乳液的制备方法,包括以下步骤:The preparation method of the high stability nanoemulsion according to the specific embodiment of the present invention comprises the following steps:
(1)取药物,溶解于溶剂中,得到药物溶解液;(1) get medicine, dissolve in solvent, obtain medicine dissolving solution;
(2)取乳化剂和1,2-丙二醇混合,得到混合表面活性剂,所述乳化剂与1,2-丙二醇的重量比为5-9:1;(2) get emulsifier and 1,2-propylene glycol and mix, obtain mixed surfactant, and the weight ratio of described emulsifier and 1,2-propylene glycol is 5-9:1;
(3)将步骤(2)得到的混合表面活性剂与步骤(1)得到的药物溶解液按照质量比为5-9:1进行均匀混合,得到混合液,然后在8000-20000r/min的高速匀浆条件下向混合液中加入水,所述混合液与水的重量比为6-9:14-11,并调节pH至7.2-7.5,高速匀浆10-60min,形成所述高稳定性纳米乳液。(3) uniformly mix the mixed surfactant obtained in step (2) and the drug dissolving solution obtained in step (1) according to a mass ratio of 5-9:1 to obtain a mixed solution, then at a high speed of 8000-20000r/min Under homogenization conditions, add water to the mixed solution, the weight ratio of the mixed solution to water is 6-9:14-11, and adjust the pH to 7.2-7.5, and homogenize at a high speed for 10-60min to form the high stability. Nanoemulsion.
本发明提供的高稳定性纳米乳液的制备方法,在制备过程中,首先将药物溶解至有机溶剂中,形成油相;然后取乳化剂与1,2-丙二醇混合以特定的比例混合,得到混合表面活性剂;将混合表面活性剂与油相的药物溶解液进行混合,并且采用碱性溶液调节体系的pH至7.2-7.5,大大增加水相的OH-含量,使纳米乳滴表面吸附更多的OH-,增加纳米乳滴Zeta电位绝对值,纳米乳滴更加稳定、经久放置不聚合。In the preparation method of the high-stability nanoemulsion provided by the present invention, in the preparation process, the drug is first dissolved in an organic solvent to form an oil phase; then the emulsifier is mixed with 1,2-propanediol in a specific ratio to obtain a mixed Surfactant; mix the mixed surfactant with the drug dissolving liquid in the oil phase, and use an alkaline solution to adjust the pH of the system to 7.2-7.5, which greatly increases the OH - content of the water phase and makes the surface of the nanoemulsion droplets adsorb more The OH - increases the absolute value of the Zeta potential of the nanoemulsion, and the nanoemulsion is more stable and does not polymerize for a long time.
优选地,步骤(1)中,所述溶剂为乙酸乙酯、肉豆蔻酸异丙酯、肉桂醛、柠檬醛、丁香酚、香芹酚中的一种。本发明提供的有机溶剂均为无毒或者低毒的有机溶剂作为药物的载体。Preferably, in step (1), the solvent is one of ethyl acetate, isopropyl myristate, cinnamaldehyde, citral, eugenol, and carvacrol. The organic solvents provided by the present invention are all non-toxic or low-toxic organic solvents as carriers of medicines.
优选地,步骤(1)中,所述药物与溶剂的重量比为1:8-12。本发明提供的药物与溶剂的重量比在上述的范围内,药物能够更好地溶解在溶剂中,形成均一稳定的药物溶解液。Preferably, in step (1), the weight ratio of the drug to the solvent is 1:8-12. When the weight ratio of the drug to the solvent provided by the present invention is within the above range, the drug can be better dissolved in the solvent to form a uniform and stable drug solution.
优选地,步骤(2)中,所述乳化剂为聚氧乙烯氢化蓖麻油RH40、聚氧乙烯氢化蓖麻油RH60、吐温-80、吐温-60、吐温-20、蓖麻油聚氧乙烯醚EL-40、司盘-80中的一种。本发明中的乳化剂具有乳化和增溶的作用,显著降低药物与水相界面的张力,利用乳化作用增加药物在水中的溶解度,从而有效提高药物的疗效。Preferably, in step (2), the emulsifier is polyoxyethylene hydrogenated castor oil RH40, polyoxyethylene hydrogenated castor oil RH60, Tween-80, Tween-60, Tween-20, castor oil polyoxyethylene A kind of ether EL-40 and Span-80. The emulsifier in the present invention has the functions of emulsifying and solubilizing, significantly reduces the interfacial tension between the drug and the water phase, and utilizes the emulsification to increase the solubility of the drug in water, thereby effectively improving the curative effect of the drug.
优选地,步骤(3)中,采用0.5-2mol/L的氢氧化钠溶液、0.5-2mol/L氢氧化钾溶液、0.8-1.2mol/L碳酸钠溶液中的一种调节pH。进一步优选地,所述pH调节至7.2-7.4。Preferably, in step (3), one of 0.5-2 mol/L sodium hydroxide solution, 0.5-2 mol/L potassium hydroxide solution, and 0.8-1.2 mol/L sodium carbonate solution is used to adjust the pH. Further preferably, the pH is adjusted to 7.2-7.4.
本发明以特定浓度的氢氧化钠、氢氧化钾或碳酸钠溶液为pH调节剂,调节体系的pH至7.2-7.5之间,优选pH在7.2-7.4,从而增加水相的OH-含量,使纳米乳滴表面吸附更多的OH-,增加纳米乳滴Zeta电位绝对值。In the present invention, a specific concentration of sodium hydroxide, potassium hydroxide or sodium carbonate solution is used as a pH regulator to adjust the pH of the system to between 7.2 and 7.5, preferably between 7.2 and 7.4, so as to increase the OH - content of the water phase, so that the The surface of nanoemulsion droplets adsorb more OH - , which increases the absolute value of Zeta potential of nanoemulsion droplets.
本发明提供一种利用上述纳米乳液制备纳米乳凝胶的方法,包括以下步骤:The present invention provides a method for preparing nanoemulsion gel by utilizing the above nanoemulsion, comprising the following steps:
(1)取上述的方法得到的高稳定性的纳米乳液,加入增稠剂,搅拌均匀,得到纳米乳粗凝胶;(1) get the high-stability nanoemulsion that above-mentioned method obtains, add thickening agent, stir, obtain nanoemulsion thick gel;
(2)向步骤(1)中得到的纳米乳粗凝胶中加入三乙醇胺,在20-25℃下以60-120r/min的速率搅拌6-12h,得到所述纳米乳凝胶。(2) adding triethanolamine to the crude nanoemulsion gel obtained in step (1), stirring at a rate of 60-120 r/min at 20-25° C. for 6-12 h, to obtain the nanoemulsion gel.
本发明提供的纳米乳凝胶的制备方法,利用上述方法制备得到纳米乳液,然后以上述的纳米乳液为水相,加入增稠剂,制备得到纳米乳粗凝胶,最后以三乙醇胺调节交联度,制备纳米乳凝胶。本发明提供的方法克服现有技术中纳米乳凝胶的制备方法中分别制备纳米乳和凝胶基质,然后经充分交联的凝胶基质与等质量的纳米乳混匀,无法保证纳米乳滴均匀分散的技术问题,确保纳米乳滴均匀分散于纳米乳凝胶基质中,保证纳米乳凝胶中药物在皮肤中横向和纵向均匀递送,提高药物的缓释效果。In the preparation method of nanoemulsion gel provided by the present invention, a nanoemulsion is prepared by the above method, then the nanoemulsion is used as a water phase, a thickening agent is added to prepare a nanoemulsion coarse gel, and finally triethanolamine is used to adjust the cross-linking to prepare nanoemulsion gels. The method provided by the present invention overcomes the problem of preparing nanoemulsion and gel matrix separately in the preparation method of nanoemulsion gel in the prior art, and then mixing the fully cross-linked gel matrix with the nanoemulsion of equal quality, which cannot guarantee the drop of nanoemulsion. The technical problem of uniform dispersion ensures that the nanoemulsion droplets are uniformly dispersed in the nanoemulsion gel matrix, ensures that the drug in the nanoemulsion gel is uniformly delivered in the skin horizontally and vertically, and improves the sustained release effect of the drug.
优选地,步骤(1)中,所述增稠剂为卡波姆934、卡波姆940或卡波姆971。Preferably, in step (1), the thickener is Carbomer 934, Carbomer 940 or Carbomer 971.
优选地,步骤(1)中,所述增稠剂的加入量为纳米乳液的0.5-1.5wt%。本发明中增稠剂的含量为0.5-1.5wt%时适应于透皮给药系统。Preferably, in step (1), the added amount of the thickener is 0.5-1.5 wt% of the nanoemulsion. When the content of the thickener in the present invention is 0.5-1.5 wt %, it is suitable for a transdermal drug delivery system.
优选地,步骤(1)中,所述增稠剂的加入量为纳米乳液的3-4wt%。本发明中增稠剂的含量为3-4wt%时适应于局部给药系统。Preferably, in step (1), the added amount of the thickener is 3-4 wt% of the nanoemulsion. When the content of the thickener in the present invention is 3-4 wt%, it is suitable for a local drug delivery system.
优选地,步骤(1)中,所述搅拌的温度为20-25℃,搅拌的速率为60-120r/min,搅拌的时间为6-12h。Preferably, in step (1), the stirring temperature is 20-25° C., the stirring speed is 60-120 r/min, and the stirring time is 6-12 h.
优选地,步骤(2)中,所述三乙醇胺的加入量0.02-0.08g/L。Preferably, in step (2), the amount of triethanolamine added is 0.02-0.08 g/L.
本发明以三乙醇胺为交联剂,上述加入量的条件下三乙醇胺能够以分子中氨基与卡波姆中大量的羧基进行充分交联反应,从而形成凝胶;该凝胶交联均匀,是均一的液晶型凝胶,凝胶内部纳米乳滴分散均匀;三乙醇胺具有碱性,能够中和卡波姆分子的酸性,有助维持纳米乳凝胶中纳米乳滴的Zeta电位水平,增强纳米乳凝胶稳定性;三乙醇胺价廉、易得便于推广应用。The present invention uses triethanolamine as the cross-linking agent, and under the condition of the above-mentioned addition amount, triethanolamine can fully cross-link with amino groups in the molecule and a large number of carboxyl groups in the carbomer to form a gel; the gel is uniformly cross-linked and is Uniform liquid crystal gel, the nanoemulsion droplets in the gel are evenly dispersed; triethanolamine is alkaline and can neutralize the acidity of the carbomer molecule, which helps to maintain the Zeta potential level of the nanoemulsion droplets in the nanoemulsion gel and enhance the nanoemulsion. Emulsion gel stability; triethanolamine is cheap, easy to obtain and easy to popularize and apply.
本发明的有益效果为:The beneficial effects of the present invention are:
本发明提供的高稳定性纳米乳液的制备方法以碱性溶液调节水相的pH至7.2-7.5,使得体系保持弱碱性,增加纳米乳液中的OH-的含量,纳米乳液中的OH-能够被吸附在纳米乳膜的表面,以增加纳米乳滴膜表面的Zeta电位绝对值,提高纳米乳液的稳定性。然后以上述方法得到纳米乳液为水相,向水相中加入增稠剂,制备得到纳米乳粗凝胶,加入三乙醇胺使纳米乳粗凝胶充分交联,一方面促进纳米乳滴均匀分散在纳米乳凝胶基质中,另一方面,提高得到的纳米乳凝胶的稳定性,保证纳米乳凝胶在药物递送过程中能够在皮肤的横向和纵向均匀分布,提高药物的缓释效果。The preparation method of the high-stability nanoemulsion provided by the present invention adjusts the pH of the water phase to 7.2-7.5 with an alkaline solution, so that the system remains weakly alkaline, and the content of OH - in the nanoemulsion is increased, and the OH - in the nanoemulsion can It is adsorbed on the surface of the nanoemulsion film to increase the absolute value of the Zeta potential on the surface of the nanoemulsion droplet film and improve the stability of the nanoemulsion. Then the nanoemulsion is obtained by the above method as the water phase, a thickening agent is added to the water phase to prepare a nanoemulsion coarse gel, and triethanolamine is added to make the nanoemulsion coarse gel fully cross-linked, on the one hand, to promote the uniform dispersion of the nanoemulsion droplets in the In the nanoemulsion gel matrix, on the other hand, the stability of the obtained nanoemulsion gel is improved to ensure that the nanoemulsion gel can be uniformly distributed in the transverse and longitudinal directions of the skin during the drug delivery process, and the sustained release effect of the drug is improved.
附图说明Description of drawings
为了更清楚地说明本发明实施例或现有技术中的技术方案,下面将对实施例或现有技术描述中所需要使用的附图作简单地介绍,显而易见地,下面描述中的附图仅仅是本发明的一些实施例,对于本领域普通技术人员来讲,在不付出创造性劳动的前提下,还可以根据这些附图获得其他的附图。In order to illustrate the embodiments of the present invention or the technical solutions in the prior art more clearly, the following briefly introduces the accompanying drawings that are used in the description of the embodiments or the prior art. Obviously, the drawings in the following description are only These are some embodiments of the present invention. For those of ordinary skill in the art, other drawings can also be obtained according to these drawings without creative efforts.
图1是对比例1得到的纳米乳液的Zeta电位值;Fig. 1 is the Zeta potential value of the nanoemulsion obtained in Comparative Example 1;
图2是实施例1得到的纳米乳液的Zeta电位值;Fig. 2 is the Zeta potential value of the nanoemulsion obtained in Example 1;
图3是实施例2得到的纳米乳液的Zeta电位值;Fig. 3 is the Zeta potential value of the nanoemulsion obtained in Example 2;
图4a是实施例7的纳米乳凝胶离心前的粒径分布;Fig. 4a is the particle size distribution before centrifugation of the nanoemulsion gel of Example 7;
图4b是实施例7的纳米乳凝胶离心后的粒径分布;Fig. 4b is the particle size distribution after the nanoemulsion gel of embodiment 7 is centrifuged;
图5a是实施例8的纳米乳凝胶离心前的粒径分布;Fig. 5a is the particle size distribution before centrifugation of the nanoemulsion gel of Example 8;
图5b是实施例8的纳米乳凝胶离心后的粒径分布;Fig. 5b is the particle size distribution after the nanoemulsion gel of
图6a是对比例2的纳米乳凝胶离心前的粒径分布;Figure 6a is the particle size distribution of the nanoemulsion gel of Comparative Example 2 before centrifugation;
图6b是对比例2的纳米乳凝胶离心后的粒径分布;Figure 6b is the particle size distribution of the nanoemulsion gel of Comparative Example 2 after centrifugation;
图7a是对比例3的纳米乳凝胶离心前的粒径分布;Figure 7a is the particle size distribution of the nanoemulsion gel of Comparative Example 3 before centrifugation;
图7b是对比例3的纳米乳凝胶离心后的粒径分布;Figure 7b is the particle size distribution of the nanoemulsion gel of Comparative Example 3 after centrifugation;
图8是实施例9的纳米乳凝胶2h皮肤内药物分布情况示意图;8 is a schematic diagram of the drug distribution in the nanoemulsion gel 2h skin of Example 9;
图9是对比例4的纳米乳凝胶2h皮肤内药物分布情况示意图;Fig. 9 is the schematic diagram of drug distribution in the nanoemulsion gel 2h skin of Comparative Example 4;
图10是实施例10的纳米乳凝胶2h皮肤内药物分布情况示意图;Figure 10 is a schematic diagram of the drug distribution in the nanoemulsion gel 2h skin of Example 10;
图11是对比例5的纳米乳凝胶2h皮肤内药物分布情况示意图。Figure 11 is a schematic diagram of the drug distribution in the skin of the nanoemulsion gel of Comparative Example 5 for 2 hours.
具体实施方式Detailed ways
为使本发明的目的、技术方案和优点更加清楚,下面将对本发明的技术方案进行详细的描述。显然,所描述的实施例仅仅是本发明一部分实施例,而不是全部的实施例。基于本发明中的实施例,本领域普通技术人员在没有做出创造性劳动的前提下所得到的所有其它实施方式,都属于本发明所保护的范围。In order to make the objectives, technical solutions and advantages of the present invention clearer, the technical solutions of the present invention will be described in detail below. Obviously, the described embodiments are only some, but not all, embodiments of the present invention. Based on the embodiments of the present invention, all other implementations obtained by those of ordinary skill in the art without creative work fall within the protection scope of the present invention.
实施例1Example 1
一种高稳定性纳米乳液,其制备方法包括以下步骤:A kind of high stability nano-emulsion, its preparation method comprises the following steps:
(1)取特比萘芬,溶解于10倍重量的柠檬醛中,得到药物溶解液;(1) get terbinafine, be dissolved in the citral of 10 times of weight, obtain medicine dissolving solution;
(2)取蓖麻油聚氧乙烯醚EL-40和1,2-丙二醇按照重量比为5:1混合,得到混合表面活性剂;(2) getting castor oil polyoxyethylene ether EL-40 and 1,2-propylene glycol is 5:1 mixing according to weight ratio, obtains mixed surfactant;
(3)将步骤(2)得到的混合表面活性剂与步骤(1)得到的药物溶解液按照质量比为5:1进行均匀混合,得到混合液,取6份所述混合液然后在8000r/min的高速匀浆条件下,向混合液中加入水至20重量份,加入1mol/L的氢氧化钠溶液调节pH至7.2,高速匀浆10min,形成所述高稳定性纳米乳液。(3) uniformly mix the mixed surfactant obtained in step (2) and the drug dissolving solution obtained in step (1) according to a mass ratio of 5:1 to obtain a mixed solution, take 6 parts of the mixed solution and then add 6 parts of the mixed solution at 8000r/ Under the condition of high-speed homogenization for 1 min, water was added to the mixed solution to 20 parts by weight, 1 mol/L sodium hydroxide solution was added to adjust the pH to 7.2, and the high-speed homogenization was performed for 10 min to form the high-stability nanoemulsion.
实施例2Example 2
一种高稳定性纳米乳液,其制备方法与实施例1的方法相同,不同的是步骤(3)中调节pH至7.5。A high-stability nanoemulsion, the preparation method of which is the same as that of Example 1, except that the pH is adjusted to 7.5 in step (3).
实施例3Example 3
一种高稳定性纳米乳液,其制备方法包括以下步骤:A kind of high stability nano-emulsion, its preparation method comprises the following steps:
(1)取青蒿素,溶解于10倍重量的香芹酚中,得到药物溶解液;(1) get artemisinin, be dissolved in the carvacrol of 10 times of weight, obtain medicine dissolving solution;
(2)取乳化剂吐温-80和1,2-丙二醇混合按照重量比为9:1混合,得到混合表面活性剂;(2) get emulsifier Tween-80 and 1,2-propanediol and mix according to weight ratio and be 9:1 to mix, obtain mixed surfactant;
(3)将步骤(2)得到的混合表面活性剂与步骤(1)得到的药物溶解液按照质量比为9:1进行均匀混合,得到混合液,取9份所述混合液然后在10000r/min的高速匀浆条件下,向混合液中加入水至20重量份,加入2mol/L的氢氧化钾溶液调节pH至7.3,高速匀浆10min,形成所述高稳定性纳米乳液。(3) uniformly mix the mixed surfactant obtained in step (2) and the drug dissolving solution obtained in step (1) with a mass ratio of 9:1 to obtain a mixed solution, take 9 parts of the mixed solution and then add 9 parts of the mixed solution at 10000r/ Under the condition of high-speed homogenization of min, water was added to the mixed solution to 20 parts by weight, 2 mol/L potassium hydroxide solution was added to adjust the pH to 7.3, and the high-speed homogenization was carried out for 10 min to form the high-stability nanoemulsion.
实施例4Example 4
一种高稳定性纳米乳液,其制备方法包括以下步骤:A kind of high stability nano-emulsion, its preparation method comprises the following steps:
(1)取萘替芬,溶解于12倍重量的乙酸乙酯中,得到药物溶解液;(1) get naftifine, be dissolved in the ethyl acetate of 12 times of weight, obtain medicine dissolving solution;
(2)取乳化剂吐温60和1,2-丙二醇混合按照重量比为8:1混合,得到混合表面活性剂;(2) get
(3)将步骤(2)得到的混合表面活性剂与步骤(1)得到的药物溶解液按照质量比为8:1进行均匀混合,得到混合液,取9份所述混合液然后在11000r/min的高速匀浆条件下,向混合液中加入水至20重量份,加入0.5mol/L的氢氧化钾溶液调节pH至7.4,高速匀浆30min,形成所述高稳定性纳米乳液。(3) uniformly mix the mixed surfactant obtained in step (2) and the drug dissolving solution obtained in step (1) according to a mass ratio of 8:1 to obtain a mixed solution, take 9 parts of the mixed solution and then add 9 parts of the mixed solution at 11000r/ Under the conditions of high-speed homogenization for min, water was added to the mixed solution to 20 parts by weight, 0.5 mol/L potassium hydroxide solution was added to adjust the pH to 7.4, and the high-speed homogenization was carried out for 30 min to form the high-stability nanoemulsion.
实施例5Example 5
一种高稳定性纳米乳液,其制备方法包括以下步骤:A kind of high stability nano-emulsion, its preparation method comprises the following steps:
(1)取伊维菌素,溶解于8倍重量的乙酸乙酯中,得到药物溶解液;(1) get ivermectin, be dissolved in the ethyl acetate of 8 times of weight, obtain medicine dissolving solution;
(2)取乳化剂聚氧乙烯氢化蓖麻油RH40和1,2-丙二醇混合按照重量比为7:1混合,得到混合表面活性剂;(2) get emulsifier polyoxyethylene hydrogenated castor oil RH40 and 1,2-propylene glycol to mix according to weight ratio and be 7:1 to mix, obtain mixed surfactant;
(3)将步骤(2)得到的混合表面活性剂与步骤(1)得到的药物溶解液按照质量比为7:1进行均匀混合,得到混合液,取8份所述混合液然后在12000r/min的高速匀浆条件下,向混合液中加入水至20重量份,加入0.8mol/L的碳酸钠溶液调节pH至7.2,高速匀浆20min,形成所述高稳定性纳米乳液。(3) uniformly mix the mixed surfactant obtained in step (2) and the drug dissolving solution obtained in step (1) according to a mass ratio of 7:1 to obtain a mixed solution, take 8 parts of the mixed solution and then add 8 parts of the mixed solution at 12000r/ Under the condition of high-speed homogenization of min, water was added to the mixed solution to 20 parts by weight, 0.8 mol/L sodium carbonate solution was added to adjust the pH to 7.2, and the high-speed homogenization was carried out for 20 min to form the high-stability nanoemulsion.
实施例6Example 6
一种高稳定性纳米乳液,其制备方法包括以下步骤:A kind of high stability nano-emulsion, its preparation method comprises the following steps:
(1)取特比萘芬,溶解于12倍重量的肉桂醛中得到药物溶解液;(1) get terbinafine, be dissolved in the cinnamaldehyde of 12 times of weights to obtain drug dissolving solution;
(2)取乳化剂蓖麻油聚氧乙烯醚EL-40和1,2-丙二醇混合按照重量比为6:1混合,得到混合表面活性剂;(2) get emulsifier castor oil polyoxyethylene ether EL-40 and 1,2-propylene glycol to mix according to weight ratio and be 6:1 to mix, obtain mixed surfactant;
(3)将步骤(2)得到的混合表面活性剂与步骤(1)得到的药物溶解液按照质量比为6:1进行均匀混合,得到混合液,取7份所述混合液然后在10000r/min的高速匀浆条件下,向混合液中加入水至20重量份,加入1.2mol/L的碳酸钠溶液调节pH至7.2,高速匀浆60min,形成所述高稳定性纳米乳液。(3) uniformly mix the mixed surfactant obtained in step (2) and the drug dissolving solution obtained in step (1) according to a mass ratio of 6:1 to obtain a mixed solution, take 7 parts of the mixed solution and then add 7 parts of the mixed solution at 10000r/ Under the high-speed homogenization condition of min, water was added to the mixed solution to 20 parts by weight, 1.2 mol/L sodium carbonate solution was added to adjust the pH to 7.2, and the high-speed homogenization was carried out for 60 min to form the high-stability nanoemulsion.
实施例7Example 7
一种纳米乳凝胶,其制备方法包括以下步骤:A kind of nano-emulsion gel, its preparation method comprises the following steps:
(1)取实施例1得到的高稳定性纳米乳液,加入增稠剂卡波姆934,在20℃条件下以120r/min的速率搅拌6h,卡波姆934的加入量为纳米乳液的1wt%,得到纳米乳粗凝胶;(1) Take the high stability nanoemulsion obtained in Example 1, add thickener carbomer 934, and stir at a rate of 120r/min for 6h at 20°C. The amount of carbomer 934 added is 1wt of the nanoemulsion % to obtain nanoemulsion coarse gel;
(2)向步骤(1)中得到的纳米乳粗凝胶中加入三乙醇胺,所述三乙醇胺的加入量0.02g/L,在20℃条件下以120r/min的速率搅拌6h,得到所述纳米乳凝胶。(2) adding triethanolamine to the nanoemulsion crude gel obtained in step (1), the amount of the triethanolamine added is 0.02g/L, and stirring at a rate of 120r/min for 6h at 20°C to obtain the Nanoemulsion gel.
实施例8Example 8
一种纳米乳凝胶,其制备方法与实施例7相同,不同的是步骤(1)中卡波姆的加入量为纳米乳液的3wt%。A nanoemulsion gel, the preparation method of which is the same as that in Example 7, the difference is that the amount of carbomer added in step (1) is 3wt% of the nanoemulsion.
实施例9Example 9
一种纳米乳凝胶,其制备方法包括以下步骤:A kind of nano-emulsion gel, its preparation method comprises the following steps:
(1)取实施例1得到的高稳定性纳米乳液,加入增稠剂卡波姆934,卡波姆934的加入量为纳米乳液的4wt%,在20℃条件下以120r/min的速率搅拌6h,得到纳米乳粗凝胶;(1) Take the high stability nanoemulsion obtained in Example 1, add thickener carbomer 934, the addition of carbomer 934 is 4wt% of the nanoemulsion, stir at a rate of 120r/min under 20°C 6h, to obtain nanoemulsion coarse gel;
(2)向步骤(1)中得到的纳米乳粗凝胶中加入三乙醇胺,所述三乙醇胺的加入量0.08g/L,在25℃条件下以60r/min的速率搅拌12h,得到所述纳米乳凝胶。(2) adding triethanolamine to the nanoemulsion crude gel obtained in step (1), the amount of triethanolamine added is 0.08g/L, and stirring at a rate of 60r/min for 12h at 25°C to obtain the Nanoemulsion gel.
实施例10Example 10
一种纳米乳凝胶,其制备方法与实施例9相同,不同的是步骤(1)中卡波姆的加入量为纳米乳液的1.5wt%。A nanoemulsion gel, the preparation method of which is the same as that in Example 9, the difference is that the amount of carbomer added in step (1) is 1.5wt% of the nanoemulsion.
对比例1Comparative Example 1
一种纳米乳液,其制备方法与实施例1相同,不同在于,步骤(3)中,调节pH至6.9。A nanoemulsion, the preparation method of which is the same as that of Example 1, the difference is that in step (3), the pH is adjusted to 6.9.
对比例2Comparative Example 2
一种纳米乳凝胶,其制备方法与实施例7的方法相同,不同在于,步骤(1)中,采用对比例1得到的纳米乳液。A nanoemulsion gel, the preparation method of which is the same as that of Example 7, the difference is that in step (1), the nanoemulsion obtained in Comparative Example 1 is used.
对比例3Comparative Example 3
一种纳米乳凝胶,其制备方法与实施例7的方法相同,不同在于,步骤(1)中,采用对比例1得到的纳米乳液。A nanoemulsion gel, the preparation method of which is the same as that of Example 7, the difference is that in step (1), the nanoemulsion obtained in Comparative Example 1 is used.
对比例4Comparative Example 4
一种纳米乳凝胶,其制备方法包括以下步骤:A kind of nano-emulsion gel, its preparation method comprises the following steps:
(1)制备纳米乳液:其制备方法与实施例1相同;(1) Preparation of nanoemulsion: its preparation method is the same as in Example 1;
(2)制备凝胶基质:取卡波姆934,加入水,所述卡波姆为水重量的8wt%,在20℃条件下以120r/min的速率搅拌6h,得到凝胶基质;(2) Preparation of gel matrix: take carbomer 934, add water, the carbomer is 8wt% of the weight of water, and stir at a rate of 120r/min at 20°C for 6h to obtain a gel matrix;
(3)取步骤(1)的纳米乳液和步骤(2)的凝胶基质,等重量混合均匀,然后加入三乙醇胺,所述三乙醇胺的加入量0.08g/L,在25℃条件下以60r/min的速率搅拌12h,得到所述纳米乳凝胶。(3) Take the nanoemulsion of step (1) and the gel matrix of step (2), mix evenly by equal weight, then add triethanolamine, the amount of triethanolamine added is 0.08g/L, under the condition of 25 ° C with 60 r The nanoemulsion gel was obtained by stirring at a rate of /min for 12 h.
对比例4提供的制备方法即为传统的制备方法。The preparation method provided in Comparative Example 4 is the traditional preparation method.
对比例5Comparative Example 5
一种纳米乳凝胶,其制备方法与对比例4相同,不同的是,步骤(2)中,所述卡波姆为水重量的3wt%。A nanoemulsion gel, the preparation method of which is the same as that of Comparative Example 4, the difference is that in step (2), the carbomer is 3wt% of the weight of water.
试验例Test example
1.pH对纳米乳液Zeta电位的影响1. The effect of pH on the Zeta potential of nanoemulsions
测试实施例1、实施例2以及对比例1中得到的纳米乳液的Zeta电位绝对值,结果见图1-3。The absolute values of Zeta potential of the nanoemulsions obtained in Example 1, Example 2 and Comparative Example 1 were tested, and the results are shown in Figures 1-3.
对比例1提供的纳米乳液的制备方法中,步骤(3)中,调节pH至6.9,实施例1中pH调节至7.2,实施例2中调节pH至7.5,从图1-3中可以看出,对比例1中的纳米乳液的Zeta电位绝对值为0.83mv左右,实施例1得到的纳米乳液的Zeta电位绝对值为8.26mv左右,实施例2得到的纳米乳液Zeta电位绝对值为21.13mv左右,本发明提供的方法得到的纳米乳液的Zeta电位绝对值明显大于对比例1的纳米乳液的Zeta电位绝对值。这说明本发明提供的纳米乳液的制备方法,通过在采用碱性溶液调节体系的pH至7.2-7.5能够大大增加水相的OH-含量,使纳米乳滴表面吸附更多的OH-,增加纳米乳滴Zeta电位绝对值,纳米乳滴更加稳定、经久放置不聚合。In the preparation method of the nanoemulsion provided by Comparative Example 1, in step (3), the pH was adjusted to 6.9, the pH was adjusted to 7.2 in Example 1, and the pH was adjusted to 7.5 in Example 2, as can be seen from Figures 1-3 , the absolute value of the Zeta potential of the nanoemulsion in Comparative Example 1 is about 0.83mv, the absolute value of the Zeta potential of the nanoemulsion obtained in Example 1 is about 8.26mv, and the absolute value of the Zeta potential of the nanoemulsion obtained in Example 2 is about 21.13mv , the absolute value of Zeta potential of the nanoemulsion obtained by the method provided by the present invention is obviously greater than the absolute value of Zeta potential of the nanoemulsion of Comparative Example 1. This shows that the preparation method of the nanoemulsion provided by the present invention can greatly increase the OH - content of the water phase by using an alkaline solution to adjust the pH of the system to 7.2-7.5, so that more OH - can be adsorbed on the surface of the nanoemulsion droplets, and the nanoemulsion can be increased. The absolute value of the Zeta potential of the emulsion droplet, the nanoemulsion droplet is more stable and does not polymerize for a long time.
2.不同制备方法得到的纳米乳凝胶动力学稳定性2. Dynamic stability of nanoemulsion gels obtained by different preparation methods
检测实施例7、实施例8、对比例2和对比例3中得到纳米乳凝胶在12000r/min的离心速率下的离心前后的粒径分布,结果如图4a-7b所示。The particle size distribution before and after centrifugation of the nanoemulsion gel obtained in Example 7, Example 8, Comparative Example 2 and Comparative Example 3 at a centrifugal speed of 12000 r/min was tested, and the results are shown in Figures 4a-7b.
图4a的纳米乳凝胶粒径分布在17.67±1.84nm,The particle size distribution of the nanoemulsion gel in Figure 4a is 17.67 ± 1.84 nm,
图4b的纳米乳凝胶粒径分布在35.37±1.67nm;The particle size distribution of the nanoemulsion gel in Figure 4b is 35.37±1.67nm;
图6a的纳米乳凝胶粒径分布在28.35±1.62nm,The particle size distribution of the nanoemulsion gel in Fig. 6a is 28.35±1.62 nm,
图6b的纳米乳凝胶粒径分布在97.03±1.91nm;The particle size distribution of the nanoemulsion gel in Figure 6b is 97.03±1.91nm;
图5a的纳米乳凝胶粒径分布在18.24±1.36nm,The particle size distribution of the nanoemulsion gel in Fig. 5a is 18.24±1.36nm,
图5b的纳米乳凝胶粒径分布在25.71±1.49nm;The particle size distribution of the nanoemulsion gel in Figure 5b is 25.71±1.49nm;
图7a的纳米乳凝胶粒径分布在27.52±1.91nm,The particle size distribution of the nanoemulsion gel in Figure 7a is 27.52 ± 1.91 nm,
图7b的纳米乳凝胶粒径分布在66.82±0.98nm;The particle size distribution of the nanoemulsion gel in Figure 7b is 66.82±0.98nm;
从图4a、4b和图6a、6b的对比以及图5a、5b和图7a、7b的对比中可以看出,相同增稠剂含量的前提下,以通过调节pH至7.2、7.5得到的纳米乳液为水相,然后通过本发明提供的方法得到的纳米乳凝胶在离心前后粒径未见明显增大,动力学稳定性好;而以pH调节至6.9得到的纳米乳液为水相制备得到的纳米乳凝胶离心前后的粒径明显增加,动力学稳定性差。这也说明,在制备纳米乳液的过程中,通过调节pH至7.2-7.5能够显著提高得到的纳米乳凝胶的动力学稳定性。From the comparison of Figures 4a, 4b and Figures 6a, 6b and Figures 5a, 5b and Figures 7a, 7b, it can be seen that under the premise of the same thickener content, the nanoemulsion obtained by adjusting the pH to 7.2 and 7.5 The particle size of the nanoemulsion gel obtained by the method provided by the present invention does not increase significantly before and after centrifugation, and the kinetic stability is good; and the nanoemulsion obtained by adjusting the pH to 6.9 is prepared in the water phase. The particle size of the nanoemulsion gel before and after centrifugation increased significantly, and the kinetic stability was poor. This also shows that in the process of preparing the nanoemulsion, the kinetic stability of the obtained nanoemulsion gel can be significantly improved by adjusting the pH to 7.2-7.5.
3.不同制备方法得到的纳米乳凝胶的药物缓释效果3. Drug sustained-release effect of nanoemulsion gels obtained by different preparation methods
对实施例9、实施例10、对比例4和对比例5得到的纳米乳凝胶2h皮肤内药物递送荧光示踪,结果见图8-11所示。The nanoemulsion gels obtained in Example 9, Example 10, Comparative Example 4 and Comparative Example 5 were subjected to intradermal drug delivery fluorescent tracing for 2 hours, and the results are shown in Figures 8-11.
从图8-11的结果可以看出,本发明实施例9提供的方法制备得到的增稠剂在4wt%的纳米乳凝胶2h内药物在皮肤内递送均匀且大部分药物滞留于表皮层,而对比例4得到的同等含量的增稠剂的纳米乳凝胶2h内药物在皮肤内递送不均一,且大量药物进入真皮层;本发明实施例10提供的方法制备得到的增稠剂在1.5wt%的纳米乳凝胶2h内药物在皮肤内递送均匀且大部分药物均匀输送至真皮层,而对比例5得到的同等含量的增稠剂的纳米乳凝胶2h内药物在皮肤内递送不均一,局部药物聚集现象明显。这说明在其他条件相同的情况下,采用本发明提供的方法制备得到的纳米乳凝胶在皮肤内递送均一,药物递送准确。而传统的方法得到的纳米乳凝胶在皮肤内递送不均匀,不均一,会出现局部药物聚集现象。It can be seen from the results in Figures 8-11 that the thickener prepared by the method provided in Example 9 of the present invention is uniformly delivered in the skin within 2 hours of the 4wt% nanoemulsion gel, and most of the drugs are retained in the epidermis, In contrast, the nanoemulsion gel with the same content of thickener obtained in Comparative Example 4 delivered unevenly within 2 hours of the drug in the skin, and a large amount of the drug entered the dermis; the thickener prepared by the method provided in Example 10 of the present invention was 1.5 The wt% nanoemulsion gel was evenly delivered in the skin within 2h and most of the drug was evenly delivered to the dermis, while the nanoemulsion gel with the same content of thickener obtained in Comparative Example 5 did not deliver the drug in the skin within 2h. Uniform, local drug aggregation phenomenon is obvious. This shows that under the same conditions, the nanoemulsion gel prepared by the method provided by the present invention has uniform delivery in the skin and accurate drug delivery. However, the nanoemulsion gel obtained by the traditional method is unevenly delivered in the skin, and the local drug aggregation phenomenon will occur.
4.不同制备方法得到的纳米乳凝胶的中纳米乳液的分散性4. Dispersibility of nanoemulsions in nanoemulsion gels obtained by different preparation methods
采用高效液相色谱法测定纳米乳凝胶中纳米乳液在凝胶基质中的分散性。在色谱条件,C18反向色谱柱,流动相(甲醇:水,8:2,v/v),流速1.1mL/min和pH3.5条件下;建立高效液相色谱法测定纳米乳凝胶中模式药物(柠檬醛和特比萘芬)含量(柠檬醛标准曲线y=3×10-7x-0.0122,r2=0.9992;特比萘芬含量标准曲线y=2×10-7x-0.0385,r2=0.9998)。随后以上述高效液相色谱条件,随机分别对5个批次本发明实施例10和对比例5的制备方法得到的纳米乳凝胶的每克凝胶药物含量进行了定量分析,分散均匀状况下实施例10应为柠檬醛40mg/g、特比萘芬4mg/g;对比例5柠檬醛20mg/mL、特比萘芬2mg/mL。The dispersibility of the nanoemulsion in the nanoemulsion gel was determined by high performance liquid chromatography. Under the chromatographic conditions, C18 reverse chromatographic column, mobile phase (methanol: water, 8:2, v/v), flow rate 1.1 mL/min and pH 3.5; establish a high performance liquid chromatography method for the determination of nanoemulsion gels Model drug (citral and terbinafine) content (citral standard curve y=3×10 -7 x-0.0122, r 2 =0.9992; terbinafine content standard curve y=2×10 -7 x-0.0385 , r 2 =0.9998). Subsequently, under the above-mentioned high performance liquid chromatography conditions, the drug content per gram of the nanoemulsion gel obtained by the preparation methods of Example 10 of the present invention and Comparative Example 5 was randomly analyzed for each gram of the gel. Example 10 should be citral 40mg/g, terbinafine 4mg/g; Comparative example 5 citral 20mg/mL, terbinafine 2mg/mL.
测试结果为:本发明实施例10得到的纳米乳凝胶中柠檬醛的含量为40.18±0.36mg/g;特比萘芬为4.12±0.23mg/g;对比例5得到的纳米乳凝胶中柠檬醛为25.12±12.22mg/g;特比萘芬为2.32±3.44mg/g。测试结果说明采用本发明的方法的得到纳米乳凝胶中每克凝胶药物的含量均一稳定,而采用对比例的方法及传统的方法制备得到的纳米乳凝胶中每克凝胶药物的含量离散程度大,不均一。The test results are: the content of citral in the nanoemulsion gel obtained in Example 10 of the present invention is 40.18±0.36 mg/g; terbinafine is 4.12±0.23 mg/g; in the nanoemulsion gel obtained in Comparative Example 5 Citral was 25.12±12.22 mg/g; terbinafine was 2.32±3.44 mg/g. The test results show that the content of each gram of gel drug in the nanoemulsion gel obtained by the method of the present invention is uniform and stable, while the content of each gram of gel drug in the nanoemulsion gel prepared by the method of the comparative example and the traditional method is uniform and stable. The degree of dispersion is large and uneven.
以上所述,仅为本发明的具体实施方式,但本发明的保护范围并不局限于此,任何熟悉本技术领域的技术人员在本发明揭露的技术范围内,可轻易想到变化或替换,都应涵盖在本发明的保护范围之内。因此,本发明的保护范围应以所述权利要求的保护范围为准。The above are only specific embodiments of the present invention, but the protection scope of the present invention is not limited to this. Any person skilled in the art can easily think of changes or substitutions within the technical scope disclosed by the present invention. should be included within the protection scope of the present invention. Therefore, the protection scope of the present invention should be based on the protection scope of the claims.
Claims (9)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010660816.2A CN111803445B (en) | 2020-07-10 | 2020-07-10 | A kind of preparation method of high stability nanoemulsion and nanoemulsion gel |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010660816.2A CN111803445B (en) | 2020-07-10 | 2020-07-10 | A kind of preparation method of high stability nanoemulsion and nanoemulsion gel |
Publications (2)
Publication Number | Publication Date |
---|---|
CN111803445A CN111803445A (en) | 2020-10-23 |
CN111803445B true CN111803445B (en) | 2022-06-17 |
Family
ID=72841721
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010660816.2A Active CN111803445B (en) | 2020-07-10 | 2020-07-10 | A kind of preparation method of high stability nanoemulsion and nanoemulsion gel |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111803445B (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112773860B (en) * | 2021-01-18 | 2022-02-08 | 澳邦制药(横琴)有限公司 | Wanying ointment and preparation method thereof |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2007009430A (en) * | 2005-02-03 | 2007-08-17 | Cinv Ag | Drug delivery materials made by sol/gel technology. |
CN101066277A (en) * | 2007-05-22 | 2007-11-07 | 西北农林科技大学 | Gel for treating skin wound and preparation method thereof |
CN101773578A (en) * | 2010-03-23 | 2010-07-14 | 江苏吴中苏药医药开发有限责任公司 | Vitex oil nanoemulsion and preparation method thereof |
CN103932896B (en) * | 2014-04-04 | 2016-09-28 | 广州立白企业集团有限公司 | A kind of nano emulsion composition that can smear out frost and preparation method thereof |
CN104382801B (en) * | 2014-12-04 | 2017-06-06 | 浙江树人大学 | A kind of autumn eggplant leaf flavonoids nano-emulsion and its gel for whitening spot-removing |
CN105193705A (en) * | 2015-09-17 | 2015-12-30 | 天津施普瑞生物科技有限公司 | Gel containing triclosan |
CN107050160A (en) * | 2017-05-25 | 2017-08-18 | 广西大海阳光药业有限公司 | It is a kind of be used to scalding, the preparation burnt and preparation method thereof |
-
2020
- 2020-07-10 CN CN202010660816.2A patent/CN111803445B/en active Active
Also Published As
Publication number | Publication date |
---|---|
CN111803445A (en) | 2020-10-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2619474C (en) | Metronidazole-based dermatological foam and emulsions for the production thereof | |
MX2011003696A (en) | Modified release emulsions for application to skin or vaginal mucosa. | |
AU2018435421B2 (en) | Topical composition | |
CN111803445B (en) | A kind of preparation method of high stability nanoemulsion and nanoemulsion gel | |
Liu et al. | Gelatin‐stabilised microemulsion‐based organogels facilitates percutaneous penetration of Cyclosporin A In Vitro and dermal pharmacokinetics In Vivo | |
CN108159414A (en) | Animal vaccine water-in-oil adjuvant and its preparation method and application | |
CN101278912A (en) | Tetrandrine nanoemulsion injection and preparation method thereof | |
CN116115502B (en) | Cosmetic compound containing stable liquid crystal structure and preparation method thereof | |
CN101181266B (en) | Biphenyl benzyl azoles emulsion agent and preparation method thereof | |
KR102585047B1 (en) | topical composition | |
Hua et al. | Preparation and evaluation of microemulsion of vinpocetine for transdermal delivery | |
CN114588102B (en) | A suspension gel for treating inflammatory skin diseases | |
CN106560175A (en) | Menthol-camphor eutectic mixture nano-emulsion in situ gel preparation | |
CN112168737A (en) | Nano emulsion and preparation method thereof | |
EP3069712A1 (en) | Transdermal colloidal solution agent | |
CN110075239A (en) | Nanoemulsions and its preparation method and application | |
JP2021518409A (en) | Topical composition | |
CN111449975A (en) | Microemulsion and preparation method thereof | |
CN106309515A (en) | Brucea javanica oil lyotropic liquid crystal nanoparticle dispersion body, raw material composition and preparation method | |
CN112263542B (en) | Desonide nanoemulsion gel composition and preparation method thereof | |
CN101756988A (en) | Compound matrine and diversine nano-emulsion preparation and preparation method thereof | |
CN1267090C (en) | Garlicin injection emulsion and its preparing method | |
CN115666571B (en) | Percutaneous absorption type preparation containing apomorphine | |
CN104382850A (en) | Rotigotine micro emulsion and micro emulsion-based gel | |
CN116019918A (en) | Competitive drug release composition, transdermal patch and preparation method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |